West Pharmaceutical Services, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 7, 2025 to Discuss Your Rights – WST

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to participate in the case without any cost or obligation [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [5].